Climb Bio (CLYM)

• Market cap: $130M
• 1 day: 1.6%
• 5 days: 0.53%
• 1 month: 1.06%
• 3 months: 10.47%
• 6 months: 62.39%
• Year to date: -8.21%
• 1 year: -40.63%
• 5 years: -88.05%
• 10 years: -88.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18